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Summary
Background Rotavirus vaccine effectiveness is reduced among children in low-income countries. Indirect 
(transmission-mediated) effects of rotavirus vaccine might contribute to the total population effect of vaccination. We 
aimed to examine risk factors for transmission of rotavirus to household contacts in Blantyre, Malawi, and estimated 
the effectiveness of rotavirus vaccine in preventing transmission of infection to household contacts.
Methods In this prospective household cohort study, we recruited children born after Sept 17, 2012, and aged at least 
6 weeks (vaccine-eligible children) with acute rotavirus gastroenteritis and their household contacts, in four 
government health facilities in Blantyre, Malawi. Clinical data, a bulk stool sample, and 1–2 mL of serum were 
collected from case children at presentation. Clinical data and stool samples were also prospectively collected from 
household contacts over 14 days from presentation. A single stool sample was collected from control households 
containing asymptomatic children who were frequency age-matched to case children. Samples were tested for 
rotavirus using semi-quantitative real-time PCR and for anti-rotavirus IgA using a semi-quantitative sandwich ELISA. 
Risk factors for household transmission of rotavirus infection and clinical disease, including disease severity and 
faecal shedding density, were identified using mixed effects logistic regression. Vaccine effectiveness against 
transmission was estimated as 1 minus the ratio of secondary attack rates in vaccinated and counterfactual 
unvaccinated populations, using vaccine effectiveness estimates from the associated diarrhoeal surveillance platform 
to estimate the counterfactual secondary attack rate without vaccination.
Findings Between Feb 16, 2015, and Nov 11, 2016, we recruited 196 case households (705 members) and 55 control 
households (153 members). Household secondary attack rate for rotavirus infection was high (434 [65%] of 
665 individuals) and secondary attack rate for clinical disease was much lower (37 [5%] of 698). Asymptomatic 
infection in control households was common (40 [28%] of 144). Increasing disease severity in an index child (as 
measured by Vesikari score) was associated with increased risk of transmission of infection (odds ratio 1·17 [95% CI 
1·06–1·30) and disease (1·28 [1·08–1·52]) to household contacts. Estimated vaccine effectiveness against transmission 
was 39% (95% CI 16–57).
Interpretation Rotavirus vaccine has the potential to substantially reduce household rotavirus transmission. This 
finding should be considered in clinical and health economic assessments of vaccine effectiveness.
Funding Wellcome Trust, US National Institutes of Health, and US National Institute of Allergy and Infectious 
Diseases.
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Introduction
Rotavirus vaccine has been introduced into over 
90 countries worldwide, including 45 low-income and 
middle-income countries.1 However, rotavirus vaccine 
effectiveness is reduced in low-income countries, where 
disease burden is highest, compared with high-income 
countries.2 Thus, despite high vaccine coverage, rotavirus 
remains the commonest cause of hospital admissions 
due to diarrhoeal disease in some low-income countries.3 
Because direct vaccine effectiveness is reduced in 
low-income and middle-income countries, additional 
transmission-media ted (indirect) effects of the vaccine 
have the potential to make important contributions to 
population-level vaccine effects. However, the magnitude 
of indirect effects that are attributable to rotavirus vaccine 
and the mechanisms which underpin them are poorly 
under stood.4
Rotavirus vaccination mimics immunity induced by 
natural rotavirus infections, which confer incremental 
protection against severe rotavirus disease to a degree 
that varies by location.5–7 Rotavirus disease severity has 
been shown to correlate with density of faecal rotavirus 
shedding in studies in India and Malawi,8 and evidence 
suggests that severity of symptoms is related to the risk 
of transmission.9 Therefore, vaccination, although not 
providing complete protection against disease, might 
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reduce the severity of gastroenteritis and diminish viral 
shedding after exposure to natural rotavirus infection, 
leading to reduced infectiousness of an index child, a 
reduced secondary attack rate in exposed households, 
and reduced rotavirus transmission.
No published data exist describing household trans-
mission of rotavirus in people in sub-Saharan Africa. 
Previous studies in high-income settings have shown a 
high secondary attack rate within families and have 
highlighted the role of infants in introducing rotavirus 
infection into households.10,11 A household transmission 
study in Ecuador showed a secondary attack rate of 55% 
for asymptomatic infection,9 and a study from India 
documented low rates of household transmission (0·54%) 
from symptomatic and asymp tomatic children with rota-
virus infection.12 However, extrapolation of data on rota-
virus transmission from high-income and middle-income 
countries to low-income countries is not appropriate 
because of fundamental differences in factors that might 
have a major influence on the risk of transmission, such as 
living environments, crowding, contact patterns, access to 
sanitation systems, host immunity, nutritional state, and 
frequency of exposure to rotavirus.4
We aimed to investigate household rotavirus trans-
mission in a semi-urban setting in Blantyre, Malawi, a 
low-income country in southern Africa. The monovalent, 
G1P[8]-containing rotavirus vaccine (RV1) was introduced 
into Malawi’s childhood immunisation programme 
in 2012. Our objectives were to (1) explore risk factors 
for transmission of rotavirus to household contacts, 
inclu ding symptom severity and density of faecal rota-
virus shedding, and (2) estimate the effectiveness of rota-
virus vaccine in preventing transmission of rotavirus 
infection to household contacts.
Methods
Study design and participants
We recruited participants for this prospective cohort study 
in four government health facilities in Blantyre, Malawi. 
Malawi is one of the poorest countries in the world, with 
70% of the population falling below the international 
poverty line in 2016.13 Government-provided health care is 
free at the point of access. Health facilities in this study 
were Queen Elizabeth Central Hospital (QECH), the 
primary referral centre for Southern Malawi; and three 
health centres (Zingwangwa, Gateway, and Madziabango). 
Details of recruitment sites are included in the appendix 
(p 1). Children born after Sept 17, 2012, and aged at least 
6 weeks (vaccine-eligible children) presenting with acute 
gastroenteritis were screened for rotavirus using a point-
of-care immuno chromatographic rapid test (Rota-Strip, 
Coris BioConcept, Gembloux, Belgium). Children testing 
positive for rotavirus (case children) were recruited 
together with their household contacts, with written 
Research in context
Evidence before this study
We searched PubMed using the terms “rotavirus” AND 
(“transmission” OR “household”), “rotavirus” AND “vaccin*” 
AND “effectiveness”, “rotavirus” AND “indirect” and “rotavirus” 
AND “herd”, for all published studies up to March 20, 2020, 
without language restrictions. Indirect effects of rotavirus 
vaccine are well documented in population-based studies from 
high-income settings. However, data from sub-Saharan Africa 
are inconsistent and limited to observational studies from a few 
countries (Kenya, Rwanda, Malawi, Zambia, and South Africa). 
Household studies have been used to better understand 
rotavirus transmission, but most studies have been done in 
high-income settings. A study from New Zealand described 
secondary attack rates of 46% for household contacts of a 
rotavirus-positive index case child, and a household study from 
the USA reported that 33% of children and 12% of adults 
exposed to an index case were infected with rotavirus. We 
identified two studies of rotavirus transmission in middle-
income countries: a study from Ecuador used quantitative real-
time PCR to identify rotavirus infection and described a 
household secondary attack rate of 55%, and a study from India 
enrolled symptomatic and asymptomatic children as index 
cases. This study used genotyping to confirm transmission and 
found a much lower secondary attack rate (0·54%). We found 
no studies of rotavirus transmission in low-income countries or 
in any country in sub-Saharan Africa.
Added value of this study
To our knowledge, this is the first study of household 
transmission of rotavirus in a low-income country, where living 
conditions and contact patterns differ fundamentally from 
those in higher-income environments. We identified very high 
levels of rotavirus transmission in this context and described a 
strong association between disease severity in an index case 
and risk of transmission to household contacts. Using these 
data, we applied novel methods to estimate a vaccine 
effectiveness of approximately 40% against rotavirus 
transmission. Rotavirus vaccination of infants is therefore 
expected to considerably reduce community transmission of 
rotavirus in low-income countries, in addition to the direct 
protection afforded to vaccinated children.
Implications of all the available evidence
Understanding the total population-level effect of rotavirus 
vaccination is crucial to realising the public health value of 
rotavirus vaccines in low-income countries, where rotavirus 
burden remains high and individual vaccine effectiveness is 
reduced compared with in high-income settings. Future 
assessments of vaccine effectiveness cost-effectiveness 
should consider the substantial effect of rotavirus vaccine 
on community-level transmission in low-income countries.
See Online for appendix
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informed assent for children and consent for parents or 
guardians. Details of screening and recruit ment are 
included in the appendix (p 2). Recruitment at QECH was 
embedded within an existing rotavirus surveillance 
platform, designed to assess rotavirus vaccine effectiveness 
using a test-negative case-control methodology as pre-
viously described (appendix p 2).14
To estimate secondary attack rates, households were 
followed up prospectively for up to 14 days after symptom 
onset in the case child. Follow-up comprised active 
surveillance for clinical disease and stool sample 
collection from household contacts to detect rotavirus 
infection (case cohort). Control households were 
recruited to define the background prevalence of 
rotavirus infection in house holds in the community. 
Control households each con tained an asymptomatic 
child, frequency-matched to case children on the basis of 
age, and were recruited from randomly generated global 
positioning system locations in Blantyre district. Controls 
were recruited from randomly generated locations rather 
than being individually location-matched to maximise 
efficiency of the study design. Control households were 
excluded if any household member had symptoms of 
gastroenteritis within 2 weeks before recruitment.
The study was approved by the University of Liverpool 
Research Ethics committee (000757), and the Malawi 
College of Medicine Research Ethics Committee 
(P.09/14/1623).
Procedures
Clinical data were collected at presentation by research 
nurses from case children, including anthropometric 
measure ments and assessment of disease severity using 
the standardised 20-point Vesikari score.15 Demographic, 
risk factor, and symptom questionnaires were completed 
for household contacts and control households on 
recruitment. Receipt of rotavirus vaccine and HIV status 
were documented from government-issued handheld 
health passports.
Participants were defined as having HIV infection if 
they tested positive on an HIV rapid test (children 
aged ≥12 months), or HIV DNA PCR (infants aged 
<12 months).16 Severe acute malnutrition was defined 
using WHO criteria of a weight-for-height Z score up to 
3 SDs from the median or mid-upper arm circumference 
of 11·5 cm or less.17
At presentation, case children with acute gastroenteritis 
had bulk stool collected for the measurement of rotavirus 
viral load and 1–2 mL of serum collected for anti-rotavirus 
IgA titres. Stool samples were collected from household 
contacts at days 5–7 and 10–12 after symptom onset 
in the case child. These timepoints were selected to 
maximise detection of secondary attack episodes, given 
published serial intervals (time between onset of disease 
in primary and secondary patients) for rotavirus disease 
of up to 11 days.18 Households were typically visited 
three times with symptom questionnaires done for all 
household members at each visit within the 14-day 
follow-up period. At the initial visit as soon after 
presentation as possible, pre-labelled sample containers 
and equipment for sample collection were left for each 
household member with instructions for use. Whenever 
possible, samples were collected on the same day that 
they were produced, or within 24 h. Samples were 
transported to the study laboratory in cool bags via study 
vehicles. In the event that samples were not obtained, 
data on clinical symptoms in household members were 
still collected. Control household members had a single 
stool sample collected at the point of recruitment.
Viral RNA was extracted from 10% stool suspension 
using Qiagen Viral RNA Mini kits (Qiagen, Hilden, 
Germany). Internal controls (Primerdesign RNA internal 
extraction control kit, Primerdesign, Southampton, UK) 
were added to each sample for quality control purposes and 
tested with a separate quantitative real-time PCR (rt-qPCR). 
Viral RNA was converted to cDNA using random primers 
(Invitrogen, ThermoFisher, Carlsbad, CA, USA).
Rotavirus was detected by use of a VP6 rt-qPCR.19 A 
standard curve, consisting of a linearised plasmid 
containing the gene that encodes VP6 from a human 
group A rotavirus of VP6 genotype 1, was included in 
each run to allow estimation of rotavirus viral load (copy 
numbers). Samples with cycle threshold (Ct) values 
greater than 35 and less than 40 on VP6 PCR underwent 
con firmatory testing with a second rt-qPCR assay 
targeting the NSP3 gene.20 Because of poor reproducibility 
in samples with very low viral loads, a rotavirus-positive 
sample was defined as containing a viral copy number of 
100 or more derived from the VP6 assay and also testing 
positive on the NSP3 assay. All samples from case 
children that were positive for rotavirus antigens and 
rotavirus rt-qPCR-positive samples from household 
members with a Ct value of 35 or less underwent G and 
P typing using a two-stage PCR with consensus and type-
specific primers using standard methods.21 Genotyping 
was done on cDNA extracted from faecal samples and 
synthesised using random primers.
Anti-rotavirus IgA geometric mean titres were 
measured using a semi-quantitative sandwich ELISA22 
and were calculated using a minimum of two values per 
sample with a coefficient of variation of less than 20%. 
Results were defined as zero if values were below 
the lower limit of detection. Rotavirus infection in 
household contacts was defined as a rotavirus-positive 
stool sample, with or without symptoms of gastroenteritis, 
and clinical disease in household contacts was defined as 
any reported vomiting or diarrhoea during the follow-up 
period.
Statistical analysis
Distributions of continuous variables were examined 
and categorical variables were tabulated to generate 
descriptive statistics. Missing observations were assumed 
to be missing completely at random. According to a 
For the G and P typing methods 
see https://apps.who.int/iris/
bitstream/handle/10665/70122/
WHO_IVB_08.17_eng.
pdf?sequence=1
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predetermined analysis plan, two-sided t tests were used 
to compare independent means of normally distributed 
data, and rank sum tests were used to compare 
non-normally distributed data. χ² or Fisher’s exact tests 
(depending on number of observations) were used to 
compare categorical variables.
Risk factors for rotavirus transmission within case 
households were identified using logistic regression 
models with a random effect to account for house hold-
level clustering. All individuals residing in case households 
were included in the analysis; however, the final regression 
models were run using observations with complete data 
for included variables. A conceptual framework (appendix 
p 7) was developed to account for the hierarchical 
relationship between predictive variables.23 Variables were 
divided into two initial groups: those relating to the 
infectiousness of the symptomatic case child and those 
relating to the susceptibility of household contacts. 
Susceptibility variables were further divided into proximal 
susceptibility (individual level), and distal susceptibility 
(household level) variables. Individual models were built 
for each group to identify risk factors of importance while 
adjusting for potential confounding. A final model was 
then built incorporating all three groups, beginning 
with distal susceptibility variables then adding proximal 
susceptibility variables and infectiousness variables. 
Separate models were built for infection and disease. All 
variables with a p value of less than 0·1 on univariable 
analysis were tested for inclusion in the final models. 
Nested models were compared using likelihood ratio tests. 
Variables were retained in the model if the p value was less 
than 0·1 at any stage of the procedures described.
This study was powered to detect a 25% reduction in 
secondary attack rates in households exposed to an index 
case with mild or moderate rotavirus disease compared 
with households exposed to severe rotavirus disease 
(Vesikari score ≥11), with 80% power and a significance 
level of 5%. Further details can be found in the 
appendix (p 6).
Estimating vaccine effectiveness against transmission
We hypothesised that by reducing disease severity in 
symptomatic children, rotavirus vaccine has the poten tial 
to reduce transmission to close contacts. Given the high 
vaccine coverage in Blantyre, we could not directly 
investigate the effect of vaccine status of the index 
case child on transmission. Vaccine effectiveness against 
transmission (VET) of rotavirus infection was therefore 
calculated using vaccine effectiveness estimates from the 
associated diarrhoeal surveillance platform to infer the 
distribution of disease severity in an unvaccinated 
population, combined with primary data on the relationship 
between disease severity and transmission from the 
household transmission study (vaccinated population).
First, children were divided into three severity groups: 
very severe disease (Vesikari score ≥15), less severe 
disease (Vesikari score <15), and asymptomatic 
infection. Secondary attack rate for infection among 
household contacts of index cases with very severe and 
less severe disease and of asymptomatic children was 
estimated using data from the household transmission 
study. The prevalence of asymptomatic infection in 
house hold members of control households was used as 
an estimate of secondary attack rate for asymptomatic 
children, accepting that this value is likely to be an 
overestimate. Receiver operating characteristic analysis 
with Youden’s index24 was used to verify that a cutoff 
of a severity score of 15 had good discriminatory 
power in differentiating risk of transmission 
(appendix p 8).
To estimate the effect of vaccination on transmission, 
we assumed that receipt of rotavirus vaccination would 
result in children with very severe disease in a 
counterfactual unvaccinated population moving into 
the less severe category and children from the less 
severe category moving into an asymptomatically 
infected category at a proportion determined by the 
respective vaccine effectiveness estimates (figure 1). 
Vaccine effectiveness against very severe (VES) and less 
severe rotavirus disease (VEM) were calculated as 
1 minus the odds ratio (OR) of two versus no doses of 
vaccine in vaccine-eligible children presenting with 
acute gastroenteritis, as previously described.25 ORs 
were estimated using logistic regression models fit to 
data from the rotavirus vaccine surveillance platform in 
Blantyre from Oct 29, 2012, to June 30, 2016, consistent 
with the most recently published vaccine effectiveness 
data.25 Under idealised test-negative case-control 
designs, the OR provides an unbiased estimate of the 
relative risk.26
The number of vaccinated children with very severe 
(SV) and less severe (MV) disease was observed in the 
household transmission study. We then estimated the 
number of children with very severe rotavirus disease 
(SU) and less severe rotavirus disease (MU) in a 
hypothetical (counterfactual) unvaccinated population 
(figure 1). The total number of children with very severe 
or less severe rotavirus disease in an unvaccinated 
population was estimated as:
Vaccine effectiveness against transmission (indicated 
by VET) was estimated as 1 minus the ratio of the 
secondary attack rates (SARs) in vaccinated and 
counterfactual unvaccinated populations using the 
following equation:
SARx is the household secondary attack rate of infection 
for a household with an index child with infection 
SV
1 –VES
MV
1 –VEM
SU MU .n + += =
(SARSPSV) (SARMPMV) (SARAPAV) .
(SARSPSU)
VET 1
+
(SARMPMU)+
+= –
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severity x, where x can be either very severe (S), less 
severe (M), or asymptomatic (A); and Pxy indicates the 
proportion of index children with rotavirus infection of 
severity x and vaccination status y, where y can be either 
vaccinated (V) or unvaccinated (U). Proportions were 
estimated as PSV = SV/n, PMV = MV/n, PAV = (n-SV-MV)/n), 
PSU = SU/n, PMU = MU/n, where SV and MV are observed 
and SU, MU, and n are calculated as previously described 
(figure 1).
Bootstrapped 95% CIs for VET were generated by 
sampling 10 000 times from the distributions of the 
corresponding parameters. Bootstrap samples of vaccine 
effectiveness (1–OR) for very severe and less severe 
disease were generated by sampling from log-normal 
distributions using the mean and SD derived from 
logistic regression models. Our estimates assume that 
the proportion of children with asymptomatic infection 
in an unvaccinated population (PAU) is similar to or lower 
than that in a vaccinated population. We did sensitivity 
analyses to assess the effect of different values of PAU and 
SARA on estimates of VET (appendix p 4).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. AB had full access to all the data in the study 
and had final responsibility for the decision to submit for 
publication
Results
Between Feb 16, 2015, and Nov 11, 2016, we recruited 
196 case households containing a symptomatic child who 
had tested positive for rotavirus, with 705 household 
members, and 55 control households containing an 
asymptomatic child who was frequency age-matched, 
with 153 household members. The median age of case 
and control children was 11·5 months (table 1). Rotavirus 
vaccine coverage was high (≥99·0% among case and 
control children). 89 (45%) of 196 case households had 
electricity at home, 68 (35%) of 195 case households (one 
household had missing data for this variable) did not have 
any member with a regular salary, and 60 (30%) of 
196 case households reported prob lems obtaining food in 
the past month (appendix p 10). Anti-rotavirus IgA titres 
in case children at presentation were low (median 4 IU/ml 
[IQR 0–30]). Viral loads in case children were high, with a 
median Ct value of 19·1 (IQR 17·2 to 22·2), corresponding 
to a median viral copy number of 1·67 × 10⁷ (1·63 × 10⁶ to 
6·37 × 10⁷). Viral loads in house hold contacts were 
markedly lower; median Ct value 34·8 (31·8 to 36·6), 
corresponding to a median copy number of 712 (256 to 
3704). Viral loads in control children and their household 
contacts were also low (median Ct value 37·9 [35·7–38·6], 
corresponding to a median copy number of 77 [34–211] 
for children; and median Ct value 37·7 [36·5–38·8], 
corresponding to a median copy number of 113 [57–297] 
for household contacts).
At least one faecal sample was collected from 665 (94%) 
of 705 individuals from 188 (96%) of 196 case households, 
with a total of 1212 samples collected. For control 
households a faecal sample was collected from 144 (94%) 
of 153 individuals from 54 (98%) of 55 control households. 
Eight households from the case cohort and one from the 
community controls either refused consent for faecal 
sample collection or were unable to provide samples. The 
secondary attack rate for infection among household 
contacts of case children was high, with 434 (65%) 
of 665 individuals positive for rotavirus (table 2). 
Clinical disease was much less common, with 48 (7%) of 
699 household contacts reporting symptoms of 
gastroenteritis. Of these, 47 (98%) had samples available 
for testing and 37 (77%) were positive for rotavirus, 
resulting in a secondary attack rate for clinical rotavirus 
disease of 5% (table 2). Six individuals had unknown 
diarrhoea history for at least one visit and were excluded 
from this analysis. Rates of clinical disease were 
significantly higher among children younger than 5 years 
compared with those from older age groups (table 2). 
The prevalence of rotavirus infection in the control 
households was 28% (40 of 144 household contacts), 
which was significantly lower than in case households 
Figure 1: Conceptual diagram of the effect of vaccination on the proportion 
of children with rotavirus infection of different degrees of disease severity
We found cases of very severe (SV) and less severe (MV) rotavirus diarrhoea 
among vaccinated children. We used the estimated vaccine effectiveness against 
very severe (VES) and less severe rotavirus diarrhoea (VEM) to infer the number of 
very severe (SU) and less severe (MU) rotavirus cases in an unvaccinated 
population. The dashed line represents the size of the potentially observable 
population (n). We explored the sensitivity of our results to different 
assumptions about the size of the asymptomatic population in the 
appendix (p 4).
Unvaccinated
children
Vaccinated
children
Unobserved
Unobserved
n=SU + MU
MU=
Observed
Very severe diarrhoea Less severe diarrhoea Asymptomatic infection
Uninfected
MV
1 – VEM 
SU= SV
1 – VES 
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(p<0·0001; table 2). The secondary attack rate for 
infection and disease were higher in households where 
index children had very severe disease compared with 
less severe disease (appendix p 12).
195 of 196 case children with remaining faecal samples 
were successfully genotyped. Of these, 60 (31%) were 
genotype G2P[4], 48 (25%) were G1P[8], 28 (14%) were 
G2[P6], and 14 (8%) were G12P[6] (appendix p 9). 
297 rotavirus samples from samples obtained from 
household contacts of case children had a Ct value 
of 35 or less and were genotyped; in 94 (32%) of these 
samples, both G and P types were the same as those 
identified in the case child (appendix p 12). Only 
15 rotavirus-positive samples from community controls 
had viral loads sufficiently high to enable genotyping, 
prohibiting meaningful comparison with the distribution 
of genotypes from case households. These data are 
shown in the appendix (p 12).
Increasing disease severity (per Vesikari score unit) in 
case children was strongly associated with transmission of 
infection to household contacts (OR 1·17 [95% CI 
1·06–1·30]; table 3). Mid-upper arm circum ference in a 
case child was also positively associated with risk of 
transmission of infection (table 3). At the household level 
(distal susceptibility factors), having at least one household 
member with a regular salary was associated with reduced 
susceptibility to infection (table 3). Con versely, difficulty 
obtaining sufficient food for the household in the past 
month was also associated with reduced susceptibility to 
infection. At the individual level (proximal suscep tibility 
factors), we found strong evidence that the proximity of 
relation ship with a case child was associated with risk of 
transmission of infection, with mothers significantly 
more likely to become infected with rotavirus than other 
adult relatives or child household contacts (table 3). 
Univariate analysis of infectiousness risk factors identified 
several clinical features associated with risk of trans-
mission of infection, including vomiting and need for 
admission to hospital; however, none of these findings 
were significant when Vesikari score was included in the 
multivariable model. Details of the univariable analysis 
can be found in the appendix (p 13).
For transmission of clinical disease, the primary 
infectiousness risk factor was disease severity in the case 
child, with a positive association between increasing 
disease severity and risk of clinical rotavirus disease 
in household contacts (OR 1·28 [95% CI 1·08–1·52]; 
table 4). We found a weak association between genotype 
of rotavirus in the case child and risk of disease 
transmission, with an increased risk of transmission 
with G1P[8] geno type compared with G2P[4], G2P[6], and 
G12P[6]. At the house hold level (distal susceptibility 
factors), use of a pit or water toilet was associated with 
reduced odds of rotavirus disease compared with having 
no toilet (appendix p 17), although this association was 
no longer significant in the final model (table 4). At the 
individual level (proximal susceptibility factors), age of 
Case children (n=196) Controls (n=55) p value*
Age, months 11·5 (8·8–15·2) 11·5 (8·2–15·4) 0·75†
Completed rotavirus vaccination
Vaccinated (two doses) 194 (99%) 55 (100%) 1·0
Unvaccinated (no dose) 2 (1%) 0 (0%) 1·0
Sex
Male 108 (55%) 26 (47%) 0·30
Female 88 (45%) 39 (53%) ··
Diarrhoea 196 (100%) 0 (0%) <0·0001
Frequency, maximum per day
1–3 173 (88%) ·· ··
5 12 (6%) ·· ··
≥6 11 (6%) ·· ··
Episodes‡
1–4 24 (12%) ·· ··
5 86 (44%) ·· ··
≥6 86 (44%) ·· ··
Vomiting 182 (93%) 0 (0%) <0·0001
Duration, days
1 23/182 (13%) ·· ··
2 59/182 (32%) ·· ··
≥3 100/182 (55%) ·· ··
Frequency, maximum per day
<5 123/182 (68%) ·· ··
≥5 59/182 (32%) ·· ··
HIV
Exposed 25/196 (13%) 6/54 (11·1%) 0·75
Infected 2/89 (2%) 0/11 (0%) 1·0
Admitted to hospital 111 (57%) ·· ··
Vesikari score 14 (12–16) ·· ··
Rectal temperature, °C
37·1–38·4 92/193 (48%) ·· ··
38·5–38·9 48/193 (25%) ·· ··
≥39·0 53/193 (28%) ·· ··
Thirst
No thirst 32 (16%) ·· ··
Thirsty 141 (72%) ·· ··
Drinks poorly 23 (12%) ·· ··
Skin pinch
Normal 56 (29%) ·· ··
Goes back slowly 104 (53%) ·· ··
Goes back very slowly 36 (18%) ·· ··
General appearance
Well and alert 94 (48%) ·· ··
Restless 83 (42%) ·· ··
Unconscious 19 (10%) ·· ··
Dehydration
None 26 (13%) ·· ··
Some (5%) 124 (63%) ·· ··
Severe (10%) 46 (23%) ·· ··
Intravenous fluid use 58 (30%) ·· ··
Oral fluid use 185 (94%) ·· ··
(Table 1 continues on next page)
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the house hold contact was significantly associated with 
risk of disease; children younger than 5 years had the 
greatest risk of disease, compared with children aged 
5–15 years and older adults (table 4).
Vaccine effectiveness was estimated to be 69% (95% CI 
–10 to 91) against very severe disease and 56% (3 to 79) 
against less severe rotavirus disease on the basis of the 
diarrhoeal surveillance dataset.25 As a result, we estimated 
that the proportion of unvaccinated children with very 
severe disease would be 0·44 (0·15 to 0·78) and the 
proportion of unvaccinated children with less severe 
disease would be 0·55 (0·22 to 0·85). By comparison, we 
estimated the proportion of vaccinated children with very 
severe disease to be 0·13 (0·06 to 0·27) and less severe 
disease to be 0·23 (0·11 to 0·47). We also estimated 
the proportion of vaccinated children who became 
asymptomatic to be 0·63 (0·27 to 0·83). We found the 
secondary attack rate to be 72% (64 to 79) for severe 
disease, 64% (57 to 69) for less severe disease, 
and 25% (16 to 35) for asymptomatic infection. 
Combining this information in equation (2), we 
estimated a VET of 39% (16 to 57; figure 2). Sensitivity 
analysis showed that VET estimates were sensitive to the 
proportion of asymptomatic individuals in an 
unvaccinated population, with VET decreasing as the size 
of the asymptomatic unvaccinated population increased, 
but VET estimates remained significantly greater 
than zero in all scenarios (appendix p 4).
Discussion
In Malawi, high secondary attack rates for rotavirus 
infection were observed in households following 
contact with a child with rotavirus gastroenteritis, 
despite high rotavirus vaccine coverage. However, the 
secondary attack rate for rotavirus disease was much 
lower. Disease severity in the case child was an important 
predictor of transmission of infection and disease to 
household contacts.
Most cases in children in our study represent failures 
of the rotavirus vaccine; high viral shedding density and 
low anti-rotavirus IgA titres at the time of presentation 
probably explained the high secondary attack rate. 
Our estimate of the secondary attack rate for rotavirus 
infection is consistent with findings from studies from 
New Zealand and Ecuador, which reported secondary 
attack rates for rotavirus infection of 48% and 55%, 
respectively.9,10 By contrast, we observed much lower 
attack rates for clinical disease, compared with 
15% reported for Ecuador and 38% for New Zealand. 
This difference could be explained by high population 
levels of rotavirus transmission in Malawi resulting in 
frequent boosting of immunity against clinical disease, 
particularly among older children and adults. Notably, in 
our study the clinical secondary attack rate was highest in 
children aged 0–4 years.27 We also observed a high 
frequency of rotavirus infection in control households. 
Although this finding is substantially higher than that 
observed in higher-income settings, such as the UK and 
Ecuador,9,28 it is consistent with findings from published 
studies from sub-Saharan Africa29,30 and is plausible given 
the high force of rotavirus infection in Malawi27 and high 
levels of poverty, crowding, and poor access to water 
and sanitation. The inconsistencies between rotavirus 
genotypes detected in case children and their household 
contacts might also reflect the high frequency of asymp-
tomatic shedding identified in the community.9
Increasing disease severity was associated with in-
creased odds of rotavirus transmission for infection and 
disease. By reducing disease severity, rotavirus vaccine 
Case children (n=196) Controls (n=55) p value*
(Continued from previous page)
Outcome
Discharged 194 (99%) ·· ··
Died 2 (1%) ·· ··
Anthropometry
Adjusted WHZ –0·59 (1·61) ·· ··
Adjusted WAZ –0·46 (1·16) ·· ··
Adjusted HAZ –0·04 (2·46) ·· ··
MUAC 13·48 (1·28) ·· ··
SAM 23/194 (12%) ·· ··
Previous diarrhoeal admission 15 (8%) 3 (6%) 0·77
Previous diarrhoeal presentation 91 (46%) 26 (47%) 0·91
Premature birth 7 (4%) 2/53 (4%) 0·69
Birthweight, kg¶ 2·96 (0·63) 2·95 (0·55) 0·89§
Ever breastfed 195 (99%) 53 (96%) 0·12
Diet includes food other than 
breastmilk
190 (97%) 48 (87%) 0·0043
IgA titres at presentation, GMC 4 (0–30) ·· ··
Data are median (IQR), n/N (%), or mean (SD), unless otherwise indicated. Denominators that do not total 196 (cases) 
or 55 (controls) result from missing data for individual variables, unless otherwise indicated. WHZ=weight-for-height 
Z score. WAZ=weight-for-age Z score. HAZ=height-for-age Z score. MUAC=mid-upper-arm circumference. SAM=severe 
acute malnutrition. GMC=geometric mean concentration. *χ² p values for differences in proportions between case 
children and control children, unless otherwise specified. †Rank-sum test. ‡Maximum frequency per day. §Two-sided 
independent t test. ¶Premature birth was defined as being born more than 1 month early.
Table 1: Characteristics of case and control children
Infection Clinical rotavirus disease
Case 
households
Control 
households
p value Case 
households
Control 
households
p value
Overall 434/665 (65%) 40/144 (28%) <0·0001* 37/698 (5%) 0/153 (0%) 0·0036*
Age, years
<5 57/88 (65%) 2/10 (20%) 0·0061* 12/91 (13%) 0/11 (0%) 0·20*
5–<15 127/193 (66%) 14/48 (29%) <0·0001* 4/197 (2%) 0/53 (0%) 0·30*
15–45 240/367 (65%) 23/84 (27%) <0·0001* 20/390 (5%) 0/87 (0%) 0·031*
>45 9/16 (56%) 1/2 (50%) 0·87* 1/18 (6%) 0/2 (0%) 0·73*
χ² p value† 0·93 0·57 ·· <0·0015 NA ··
One value for age was missing in household members with rotavirus infection and two values were missing for 
age in household members with rotavirus disease. NA=not applicable. *χ² p value comparing difference in proportion 
between case children and controls. †χ² p value for difference in proportion between children younger than 5 years and 
those aged 5 years and older.
Table 2: Secondary attack rates for rotavirus infection and clinical disease
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has the potential to reduce the infectiousness of a 
symptomatic child even in the event of clinical vaccine 
failure. This effect has been described with other 
pathogens such as Bordetella pertussis, but not yet with 
rotavirus.31 In this study, we estimated that in a semi-
urban population in Malawi, with high rates of rotavirus 
transmission, rotavirus vaccine substantially reduces 
household rotavirus transmission, which could have a 
considerable effect on the burden of rotavirus disease in 
the community, and is consistent with previous estimates 
of indirect effectiveness of rotavirus vaccination from 
Malawi from hospital-based studies and mathematical 
models.25,27 By contrast, horizontal transmission of 
vaccine-derived virus is unlikely to make a meaningful 
contribution to indirect effects in this setting because 
such transmission within households is rare.32
No regular income in the household increased the risk 
of transmission of infection. This finding probably 
reflects relative poverty compared with other study 
participants, which could increase rotavirus transmission 
for reasons including crowding, sanitation, carer 
education levels, or other unmeasured factors.33 Close 
contact and proximity of relationship to the index child 
also increased the risk of transmission of infection, 
emphasising that improved personal and hand hygiene 
and behavioural measures might be impor tant for 
preventing rotavirus transmission within house holds.34 
Rotavirus genotype G1P[8] was weakly associated with an 
increased risk of transmission, consistent with the 
global predominance of G1P[8] before the widespread 
introduction of vaccination.35
Our study has important limitations. The direction of 
infection cannot be defined with certainty using this 
study design because households were recruited only 
when an index child presented with rotavirus gastro-
enteritis; however, the pattern of transmission supports 
the notion of young infants bringing rotavirus into the 
household. Our analysis of the secondary attack rate by 
age did not fully account for the clustered nature of the 
data, and results should be interpreted with this in 
mind. Nevertheless, the findings are consistent with the 
Odds ratio (95% CI) p value
Infectiousness risk factors
Vesikari score in case child 1·17 (1·06–1·30) 0·0029
MUAC in case child 1·32 (1·06–1·66) 0·015
Distal susceptibility factors
Number of adults with salary in household
None Ref ··
≥1 0·44 (0·24–0·80) 0·0069
Problems getting food in the past month (%)
No Ref ··
Sometimes or often 0·58 (0·31–1·06) 0·077
Proximal susceptibility factors
Relationship with child
Mother Ref ··
Other adult relative 0·29 (0·16–0·50) <0·0001
Child contact 0·44 (0·26–0·74) 0·0020
n=645 observations with complete data included in the model. Odds ratios for 
Vesikari score and MUAC are per variable unit. MUAC=mid-upper-arm 
circumference.
Table 3: Risk factors for transmission of rotavirus infection
Odds ratio (95% CI) p value
Infectiousness risk factors
Vesikari score in index child 1·28 (1·08–1·52) 0·0048
Rotavirus genotype in index child
G1P[8] Ref ··
G2P[4] 0·36 (0·12–1·03) 0·059
G2P[6] 0·43 (0·11–1·64) 0·22
G12P[6] 0·82 (0·23–2·95) 0·76
Other 1·10 (0·44–2·71) 0·84
Distal susceptibility factors
Toilet type
None Ref ··
Simple pit or VIP 0·56 (0·11–2·83) 0·48
Water toilet 0·42 (0·03–5·96) 0·52
Proximal susceptibility factors
Household member age, years
<5 Ref ··
5–<15 0·13 (0·04–0·46) 0·0014
15–45 0·38 (0·17–0·92) 0·031
>45 0·35 (0·04–3·22) 0·35
n=681 observations with complete data included in the model. Odds ratio for 
Vesikari score is per variable unit. VIP=ventilated improved pit latrine.
Table 4: Risk factors for transmission of rotavirus disease
Figure 2: Distribution of estimates for vaccine effectiveness against transmission
The histogram of 10 000 bootstrap samples of the estimated vaccine 
effectiveness against transmission is plotted. VET=vaccine effectiveness against 
transmission.
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regression analysis of risk factors for transmission, 
which did account for household clustering. We did not 
differentiate vaccine-type G1P[8] rotavirus strains from 
wild-type virus in this study, but we have previously 
shown that household transmission of rotavirus vaccine 
virus occurs infrequently in this population,32 and 
therefore vaccine-derived virus is unlikely to have 
contributed to rotavirus detection in stool. Our estimate 
of vaccine effectiveness against transmission assumed 
that asymptomatic infections contribute a small amount 
to the overall secondary attack rate, and that the 
prevalence of asymptomatic infection is similar or lower 
in an unvaccinated population. The prevalence of 
asymp tomatic infections among unvacci nated infants 
and vaccine effectiveness against asymp tomatic 
infection are unknown. Sensitivity analysis showed that 
vaccine effectiveness against transmission decreased as 
the size of the asymptomatic unvaccinated population 
increased, but remained significantly greater than zero 
in all scenarios tested. Vaccine effectiveness against 
transmission is dependent on locally specific parameters 
and our estimate might not be generalisable to other 
settings. Finally, in our population we could not directly 
measure the effect of vaccine status on household 
transmission of rotavirus because of high vaccine 
coverage. Our methods address this limitation by 
providing a quantitative estimate of the effect of 
vaccination on transmission, informed by primary 
transmission data from a vaccinated population and 
vaccine effectiveness estimates from the same 
recruitment platform.
Despite sustained high coverage of rotavirus vaccine 
in Malawi and other low-income African countries, the 
burden of rotavirus disease remains high. Indirect (herd) 
protection through vaccination should be considered 
together with direct vaccine effectiveness estimates 
in future clinical and health economic assessments 
of rotavirus vaccination, particularly in low-income, 
high -burden environments.
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